EATG » Hepatitis

Hepatitis

VBI Vaccines completes vaccination in PROTECT Phase 3 clinical study for Sci-B-Vac® hepatitis B vaccine

-- Vaccination complete in 1,537 subjects in PROTECT Phase 3 study -- No vaccine-related adverse events have been observed to-date -- Top-line data expected mid-2019 October 16, 2018: VBI Vaccines…

Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

PHILADELPHIA – The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as…

Infections common in patients coinfected with HIV/HCV taking direct-acting antivirals

In patients with HIV/hepatitis C virus (HCV)-coinfection who receive oral direct-acting antiviral agents (DAAs) severe infections are relatively common, according to study results published in the Journal of Viral Hepatology. The…

What are the barriers to hepatitis C treatment in prisons?

Lack of privacy, lack of peer support and lack of harm reduction are perceived as the biggest barriers to improving the uptake of direct-acting antiviral treatment for hepatitis C among…

Not all people are equally vulnerable to hepatitis C – new study

The hepatitis C virus (HCV) infects around 1% of the human population and is a devastating pathogen. In most people, it silently infects the liver for decades, often causing life-threatening…

Latest issue of Journal of Virus Eradication now online

The Journal of Virus Eradication provides a specialist, open-access forum and fast-track pathway to publish work in the rapidly developing field of virus eradication, particularly of HIV, HBV and HCV.…

Hepatitis C elimination in people living with HIV in the UK is feasible by 2021, British HIV Association says

Hepatitis C coinfection can be eliminated in people living with HIV in the United Kingdom by 2021, the British HIV Association said today (October 10). “The UK can be the…

Cocrystal Pharma announces clinical trial agreement for Phase 2a study of CC-31244

Cocrystal Pharma announces clinical trial agreement for investigator-initiated Phase 2a study in Hong Kong of CC-31244 for ultra-short treatment of hepatitis C virus -- Humanity & Health Research Centre to…

Ireland: Antivirals cure up to 98% of hepatitis C patients since 2014

Use of revolutionary drugs has led to ‘a triumph of science’, says hepatologist Up to 98 per cent of patients with hepatitis C virus have been cured thanks to the…

Janssen announces exclusive, worldwide license agreement to develop and commercialize a new treatment for hepatitis B

Janssen announces exclusive, worldwide license agreement with Arrowhead Pharmaceuticals to develop and commercialize a new treatment for chronic hepatitis B viral infection Agreement expands breadth of Janssen's hepatitis B virus…

1 2 3 89